Pipeline

Two drug candidates in advanced clinical phases

Pipeline

PledOx®

PledOx® (calmangafodipir) is a first-in-class drug candidate, the first of its kind designed to prevent nerve damage associated with chemotherapy, without adversely affecting the anti-cancer effect. A Phase III study is initiated.

Read more

Status in PledOx®
Market approval
Phase III
Phase II
Phase I
Preclinical phase
 

Aladote®

Aladote® is a first-in-class drug candidate, the first of its kind developed to reduce liver damage due to paracetamol poisoning. A proof of principle study, Phase IIb has been successfully completed.

Read more

Status in Aladote®
Market approval
Phase III
Phase II
Phase I
Preclinical phase
 

Share

Facebook
Twitter
LinkedIn
RSS

Contact us

Address: Grev Turegatan 11 C, 114 46 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@pledpharma.com